Number of pages: 100 | Report Format: PDF | Published date: March 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global aplastic anemia treatment market was valued at US$ 9.6 billion in 2022 and is expected to register a revenue CAGR of 7.5% to reach US$ 18.4 billion by 2031.
Aplastic Anemia Treatment Market Fundamentals
Anemia is when the body does not have sufficient healthy red blood cells to carry oxygen to the tissues and organs. This can occur for various reasons, including a deficiency in iron, vitamin B12, or folate, as well as chronic diseases, infections, and genetic disorders. Similarly, aplastic anemia is a rare and serious blood disorder that occurs when the bone marrow fails to produce enough red blood cells, white blood cells, and platelets. This can lead to various symptoms, including fatigue, shortness of breath, and an increased risk of infections and bleeding. While aplastic anemia can be life-threatening, several treatment options are available to help manage the disease.
Aplastic anemia treatment typically involves a combination of approaches, including blood transfusions, drug therapy, and bone marrow transplantation. Blood transfusions can help replace the blood cells that are not produced by the bone marrow, while drug therapy can stimulate the production of new blood cells. In more severe cases of aplastic anemia, bone marrow transplantation may be necessary to replace the damaged bone marrow with healthy cells. The specific treatment approach for aplastic anemia will depend on a range of factors, including the severity of the disease, the age and overall health of the patient, and the underlying cause of the condition. Ongoing research is focused on developing new and more effective treatment options for aplastic anemia and identifying ways to improve the safety and efficacy of current treatment approaches.
Aplastic Anemia Treatment Market Dynamics
The rising prevalence of aplastic anemia is the major driver for the revenue growth of the global aplastic anemia treatment market. For instance, according to the National Center for Biotechnology Information article of July 2022, aplastic anemia has an incidence rate of 0.6 to 6.1 per million people. The advancement of new and improved medical technologies is also propelling the revenue growth of the aplastic anemia treatment market. Although bone marrow transplantation remains an important treatment option for aplastic anemia, researchers are looking for innovative ways to make the surgery safer and more successful. Additionally, as the awareness about aplastic anemia increases among patients and healthcare providers, the demand for effective treatments is increasing. Patients and healthcare providers are seeking new and effective treatment options for the disease, boosting the revenue growth of the global aplastic anemia treatment market. Furthermore, with the increasing healthcare expenditure globally, the demand for effective treatments for aplastic anemia is also increasing. As patients become more aware of the disease and its treatment options, they are willing to spend more on treatments that can help manage their condition, which is also helping in the revenue growth of the global aplastic anemia treatment market. The robust drug pipeline offers promising, advanced, and efficacious treatment options, contributing to market revenue growth.
However, the cost of treating aplastic anemia can be quite high, which may limit access to treatment for some patients. However, there may be limited awareness of aplastic anemia among the general public and healthcare providers, leading to delayed diagnosis and treatment. Additionally, limited availability of treatment options, side effects of available treatment, and tedious regulatory procedures are some of the restraints impeding the overall aplastic anemia treatment market revenue growth.
Aplastic Anemia Treatment Market Ecosystem
The global aplastic anemia treatment market is analyzed from four perspectives: treatment type, disease type, end-user, and region.
Aplastic Anemia Treatment Market by Treatment Type
Based on the treatment type, the global aplastic anemia treatment market is segmented into bone marrow transfusion/stem cell therapy, blood transfusion, and drug therapy.
The bone marrow transfusion segment dominated the market with the principal revenue share in 2022, as it is often the only curative treatment option for patients with severe aplastic anemia. Bone marrow transplantation, also known as stem cell transplantation, is a type of treatment for aplastic anemia that involves replacing damaged or diseased bone marrow with healthy bone marrow cells from a donor. A bone marrow transplant provides a patient with healthy stem cells, which develop into various types of blood cells. These stem cells are derived from marrow, the soft, fatty tissue found within the bones, and are used to replace marrow that is no longer functioning effectively. Aplastic anemia was among the first disorders to benefit from bone marrow transplantation. Additionally, ongoing research is focused on improving the safety and effectiveness of this treatment and expanding the pool of potential donors through initiatives such as cord blood banking. These factors contribute to the revenue growth of the bone marrow transfusion segment.
The drug therapy segment dominated the market with the second-largest revenue share in 2022, as it is the option for patients who cannot undergo bone marrow transfusion. Drug therapy includes the use of medications to stimulate the production of blood cells in the bone marrow. This type of treatment is commonly used for patients with mild to moderate aplastic anemia and those who are not suitable candidates for other treatment options. It includes immunosuppressive drugs (Cyclosporine, Mycophenolate Mofetil), revenue growth factors (Darbepoetin Alfa), and alkylating agents (Cyclophosphamide). These medications target specific pathways in the body that produce blood cells.
Aplastic Anemia Treatment Market by Disease Type
Based on the Disease Type, the global aplastic anemia treatment market is segmented into acquired aplastic anemia and inherited aplastic anemia.
The acquired aplastic anemia segment dominated the market with the largest revenue share in 2022, owing to its rising incidence. For instance, according to National Organization for Rare Disorders, 500-1,000 new cases of aplastic anemia are diagnosed in the U.S. every year. Acquired aplastic anemia is a type of aplastic anemia that develops due to damage to the bone marrow stem cells. This condition can result from exposure to toxins, infections, or certain medications, among other factors, and can develop at any age. Furthermore, the symptoms differ on a case-by-case basis. Certain individuals may experience mild symptoms that remain consistent for an extended period. In contrast, others might encounter severe symptoms that potentially lead to critical complications. These overall factors contribute to the revenue growth of the acquired aplastic anemia segment.
Similarly, the inherited aplastic anemia segment also accounted for a significant revenue share dominated in 2022. Inherited aplastic anemia (IAA) is a rare form of aplastic anemia caused by genetic mutations that affect the production of blood cells in the bone marrow. This type of aplastic anemia is typically diagnosed in childhood or early adulthood. It can have a significant impact on a patient’s quality of life.
Aplastic Anemia Treatment Market by End-user
Based on the end-user, the global aplastic anemia treatment market is segmented into hospitals, research institutes, and others.
The hospitals segment is a key player in the aplastic anemia treatment market with the largest revenue share in 2022, owing to the significant footfall. Hospitals play a key role in diagnosing, treating, and managing aplastic anemia. They provide various services for patients with aplastic anemia, including diagnostic testing, blood transfusions, drug therapy, bone marrow transplantation, and supportive care. They are also responsible for managing the complex medical needs of patients with aplastic anemia, which may include managing complications such as infections, bleeding, and anemia. In addition, hospitals may provide counseling and support services to help patients and their families cope with the emotional and psychological impact of the disease. These overall factors contribute to the revenue growth of the hospital segment.
Aplastic Anemia Treatment Market by Region
Geographically, the global aplastic anemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global aplastic anemia treatment market with the largest revenue share in 2022, attributed to the presence of the key market players, substantial healthcare spending, and well-developed technology. Additionally, companies across the region are continuously involved in raising funds to improve their existing process in the aplastic anemia treatment field, which is also helping in the market revenue growth. For instance, in March 2023, the U.S. Food and Drug Administration approved mitapivat (Pyrukynd) tablets for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The oral PK activator, developed by Agios Pharmaceuticals, is the first approved disease-modifying therapy for this disease. The approval was based on data from ACTIVATE and ACTIVATE-T Phase 3 Studies and supported treatment regardless of transfusion status.
Aplastic Anemia Treatment Market Competitive Landscape
The prominent players operating in the global aplastic anemia treatment market are:
Aplastic Anemia Treatment Market Strategic Developments
The global aplastic anemia treatment market was valued at US$ 9.6 billion in 2022.
The global aplastic anemia treatment market is expected to reach US$ 18.4 billion by 2031.
The revenue CAGR of the aplastic anemia treatment market during the forecast period will be 7.5% from 2023 to 2031.
The limited availability of treatment options, side effects of available treatments, and tedious regulatory procedures restrict the global market revenue growth to its full potential.
Some prominent players operating in the global aplastic anemia treatment market are Novo Nordisk AS, GlaxoSmithKline plc, Regen Biopharma Inc., Bluebird Bio Inc., and Ligand Pharmaceuticals Incorporated.
*Insights on financial performance are subject to the availability of information in the public domain